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CHAPTER 1 
 
INTRODUCTION 
 
Bcl-2 Family Members 
The Bcl-2 family of proteins are key regulators of caspase-dependent and 
caspase-independent apoptosis.  Stressors such as the activation of the cell surface death 
receptor and DNA damage are known to activate caspases, which in turn stimulate cell 
death [1].  Classified according to function and structure, the Bcl-2 family of proteins 
have been divided into three categories: anti-apoptotic (i.e. Bcl-2, Bcl-xl), proapoptotic 
(with multiple domains—Bax, Bak), and Bcl-2 homology 3 (BH3)-only (i.e. Bid, Puma, 
Bad) [1].   
Many BH3-only proteins have been extensively studied with regards to cell death 
signaling and cell cycle.  Bid has been shown to affect the S phase checkpoint after DNA 
damage by ataxia-telangiectasia mutated (ATM) [2, 3]. BAD binds only selective subsets 
of antiapoptotic proteins, namely Bcl-2 and Bclx.  Furthermore, BAD dephosphorylation 
at site S112 has been described as a “gatekeeper” for cell death activation [4, 5].  
Recently, it was suggested that BH3-only proteins engage the antiapoptotic relatives 
which regulate multidomain proapoptotic proteins (Bax and Bak) to induce apoptosis [6] 
[7].   
 
 
 
2 
BAD Phosphorylation Status Regulates Function 
 The phosphorylation status of BAD is key to its activity [4].  Reported 
phosphorylation sites on murine BAD include S112, S128, S136, S155, S170, and 
T201[4, 8, 9].  BAD S128, S136, and T201 have all been proposed to be key regulators of 
apoptotic activity[4, 8]; some upstream kinases for these sites have been identified.  Pim 
3 has been reported to phosphorylate BAD predominantly at S136, but also S155 and 
S170, and least intensely S112 [10].  PKA is known to phosphorylate BAD at S112 and 
S155 to enhance cell survival [11].  AKT is an important kinase that phosphorylates BAD 
at S136 [12].  CDC2 is known to phosphorylate BAD at S128 [13], while another report 
identifies JNK to phosphorylate T201 on BAD [9].  While one report suggests that JNK 
phosphorylates BAD at S128 [14], another refutes that claim [15].   
 
 
Figure 1: Model of BAD regulation [4].  Under +IL3 conditions, 14-3-3 caps the S112 
and S136 phosphorylated BAD sites (shown also is phosphorylated S155).  During 
induction of cell death, 14-3-3 loosens its tight binding to BAD, exposing the S112 site to 
PP2A.  Upon S112 dephosphorylation, 14-3-3 dissociates, and S1136 and S155 are 
subsequently dephosphorylated under conditions of cell death.  
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  The phosphorylation status of BAD impacts its binding partners; 14-3-3 is known 
to bind and protect BAD phosphorylation sites S112 and S136, sequestering BAD in the 
cytoplasm (Figure 1).  However, under conditions of cell death, 14-3-3 becomes loose 
and exposes the phosphorylated S112 site to phosphatases.  Upon PP2A 
dephosphorylation of S112, 14-3-3 detaches from BAD and S136 and S155 sequentially 
get dephosphorylated.  The dephosphorylated BAD translocates to the mitochondria to 
bind Bcl-xL [4].  In one study conducted in neuronal cells, a cell-cycle dependent 
dissociation of BAD with 14-3-3 was attributed to BAD phosphorylation at S128 [16].   
 
14-3-3 is a Regulatory Protein 
 14-3-3 proteins are a family of dimeric proteins that oversee eukaryotic cellular 
functioning in areas including protein kinase signaling pathways, apoptosis, and cell-
cycle progression [17].  The dimeric structure of 14-3-3 facilitates its ability to act as a 
phosphoserine/phosphothreonine-binding protein [18, 19] [17]; the binding of 14-3-3 to a 
conserved phospho-motif site protects the phosphorylation sites and directs the bound 
protein’s function.  Additionally, 14-3-3 can function as an adaptor protein bridging two 
proteins [17].  This protein-protein interaction facilitates the activation of MAPK 
signaling pathways, prevents apoptosis, and maintains DNA damage checkpoints. 
 It is known that 14-3-3 can undergo post-translational modifications by 
phosphorylation [19].  Phosphorylation of 14-3-3 by JNK at S184 [20] releases 14-3-3 
from BAD in vitro[21].  Furthermore, 14-3-3 monomers have been reported to be 
phosphorylated at S58, which prevents dimerization, but does not prevent binding to a 
downstream target [18].  
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Mitogen Activated Protein Kinase (MAPK) Family 
  The MAPK family plays prominent roles in transducing extracellular signals in 
processes such as cell growth, survival, and death [22].  At least three subgroups of the 
MAPK family have been described: the  extracellular signal-regulated kinases (ERKs), c-
jun N-terminal kinases (JNK), and p38 MAPK [23].  While both JNK and p38 MAPK 
respond to stress such as ultraviolet radiation, heat, and inflammatory cytokines, ERK 
activation is centered on mitogenic stimuli including cytokines [22].  In order for ERK, 
JNK, or p38 to become activated, specific tyrosine and threonine motif residues must be 
phosphorylated [22].  
While p38 has been loosely linked to promotion of cell growth in some cell lines, 
overwhelming evidence suggests that p38 is linked with apoptosis [23].  One study has 
suggested that p38 acts downstream of caspase activation [23].  In another, employing 
doxorubicin-induced endothelial cell death, p38 has been shown to inhibit BAD 
phosphorylation in a PI3K/Akt-dependent manner, thereby contributing to cell death [24].   
JNK has also been linked with cell death, particularly modifying protein-protein 
interactions to yield a specific response.  JNK has been reported to phosphorylate 14-3-3 
to disociate it from its binding partner c-Abl, resulting in c-Abl translocation to the 
nucleus [25].  JNK has been reported to phosphorylate BAD at T201 thereby promoting 
cell survival [9].  A report has suggested that reactive oxygen species, which contribute to 
apoptosis signaling, is at least partially mediated by activated JNK [26].  
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Summary 
 Although the signaling mechanisms of the apoptotic pathway have been 
extensively studied, there is still much left unknown.  Because key phosphorylation sites 
on BAD (and hence it’s proapoptotic function) is under tight regulation by 14-3-3, this 
thesis examined the mechanism of the BAD-14-3-3 complex dissociation.  It was 
hypothesized that a novel phosphorylation event occurring either on 14-3-3 or BAD, or 
the interaction of an unknown binding partner may aid in the dissociation of 14-3-3 to 
BAD under conditions of cell death.  Methods used in these investigations included: 
Mass Spectrometry, kinase assays,  pulldown experiments, and western blots.  Several 
novel binding partners to BAD were identified in either a condition of cell life or cell 
death, including: p38, CDC2, Beclin-1, BAX, cytochrome c1 oxidase, and voltage-
dependent anion-selective channel proteins 1, 2, and 3.  32P kinase assays suggested that 
p38 phosphorylates a novel site on BAD, serine 6 (S6).  The phosphorylation state of 
BAD S128 was observed 3-7 hours after cell death stimulation and was independent of 
p38 activation.   Under cell life and death conditions, no new phosphorylation sites or 
monomeric changes on 14-3-3 were observed; p38 was concluded not to phosphorylate 
14-3-3.  Future studies examining the novel S6 BAD phosphorylation site may yield 
insights on the regulation and functional significance of this event in apoptosis.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Cell Culture and Reagents 
 The hematopoietic pro-B cell line FL5.12 were grown in Iscoves Modified 
Dulbeccos Medium (IMDM, Sigma #i3390) media supplemented with 10% Fetal Bovine 
Serum (FBS, Gibco #10437-028), 1% Penicillin/Streptomycin (P/S) (BioWhittaker #17-
602E), 1% L-Glutamine (Glu, BioWhittaker #17-605E), and Interleukin-3 (IL3).  NIH 
3T3 cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma #D5796) 
media supplemented with 10% calf serum (BioWhittaker, 14-401F), 1% P/S, and 1% 
Glutamine.    
The chemical inhibitors to p38 (SB203580) and CDC2 (Olomoucine, sc-3509) 
were from Santa Cruz biotechnology; the JNK inhibitor SP600125 was obtained from 
Alexis Biochemicals.  Total BAD mouse antibody was from BD Transduction 
Laboratories (#610392), while 14-3-3β K-19 rabbit antibody was obtained from Santa 
Cruz Biotechnology (sc-629).  Anti-Bad phospho-Serine 128 antibody was obtained from 
three sources: originally from the Bonni lab (Harvard University), BioSource  (#44-
523G), and Chemicon (AB3567).  Total p38 (A-12) antibody was from Santa Cruz (sc-
7972); active p38 was obtained from Cell Signaling (9211S).  Commercial HisBAD 
(#14-281) and purified kinase p38 came from Upstate (#14-210), and purified CDC2 
from New England Biolabs (NEB, #P6020S).  PKA was a generous gift from Dr. Jackie 
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Corbin (Vanderbilt University).  Isoelectric (pI) strips were from BioRad, while the 
colloidal blue kit was from Invitrogen.  Glycine was obtained from MP BioMedicals.   
 
Cell Death Assay 
It is known that removing the cytokine IL3 from the media results in cell death; 
for experiments examining potential changes during cell death, the FL5.12 cells were 
washed three times with PBS, plated in –IL3 media (IMDM supplemented with 10% 
FBS, 1% P/S and 1% Glu), and grown in an incubator kept at 37°C with 5% CO2.  3T3 
cells were arrested as previously reported [27]. 
 
Generation of HisBAD mutant constructs 
Wild type (pcDNA BAD WT) or 112, 136, 155 serine to alanine mutation (3A) 
(pMSCV IRES GFP BAD 3A) templates were used as polymerase chain reaction (PCR) 
template deoxyribonucleic acid (DNA).  The following internal primers were used to 
introduce the 128A mutation (in bold, all written 5’->3): forward- 
ATGGAGGAGGAGCTTGCCCCTTTTCGAGGA; reverse- 
TCCTCGAAAAGGGGCAAGCTCCTCCTCCAT.  These PRC reactions were carried 
out at 94° for 10 minutes, 20 cycles of  94°, 50°, and 72° each for one minute, extended 
at 72° for 5 minutes, and kept indefinitely at 4°.  Once the BAD sequence contained the 
desired point mutations, the following primers were used to introduce desired restriction 
sites for pQE-30 subcloning: forward-
AAAAAAGCATGC(Sph1)GGATCC(BamH1)ATGGGAACCCCAAAGCAGCCCTCG; 
reverse- 
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AAAAAAAAACTCGAC(Sal1)AAGCTT(Hind3)TCACTGGGAGGGGGTGGAGCCT
CCTTT.  Different primers were used to introduce other restriction enzymes into the 
pMSCV vector: forward (with 6xHis tag)-
AAGAATTC(EcoR1)CTCGAG(Xho1)GCCGCCACC(Kozak)ATGCATCACCATCAC
CATCAC(6XHis)ATGGGAACCCCAAAGCAGCCCTCG; forward (with no 6xHis tag):  
AAGAATTC(EcoR1)CTCGAG(Xho1)GCCGCCACC(Kozak) 
ATGGGAACCCCAAAGCAGCCCTCGCCCTCG; reverse- 
AACTCGAC(Sal1)GAATTC(EcoR1)TCACTGGGAGGGGGTGGAGCCTCCTTT.  
PCR conditions were carried out at 94° for 10 minutes, 35 cycles of  94°, 55°, and 72° 
each for one minute, extended at 72° for 5 minutes, and kept indefinitely at 4° for all 
constructs except the 4A or 128A creations.  PCR products were then analyzed on 
ethidium bromide stained 1% agarose gels, gel extracted (Qiagen QIAquick gel 
extraction Kit #28704), ligated into the Topo vector (Invitrogen Topo TA Cloning kit 
#45-0640), transformed into competent DH5α cells, plated on X-gal treated ampicillin 
plates, and grown overnight at 37°.  White colonies were picked and grown in Luria-
Bertani Media (LB) for less than 16 hrs at 37° with 250 rpm shaking.  Plasmid DNA was 
purified (Qiagen miniprep) and digested with either Xho1/EcoR1 for pMSCV-bound 
inserts or Sph1/Hind3 (from New England Biolabs, NEB) for pQE-30 inserts, and placed 
at 37° for 2 hrs or more.  Completed digestions were then run on an ethidium bromide 
stained agarose gel; colonies that appeared to contain the correct sized insert were then 
sent to the Vanderbilt Sequencing Core facility for sequence verification.  Once sequence 
verification was obtained, Topo colonies were digested with appropriate pairs of 
9 
endonucleases, gel extracted, and ligated into either pQE-30 or pMSCV for further use in 
bacteria or cells.  
 
Construction of Cell Lines 
FL5.12 cells over expressing 3xFlag-BAD-Myc (FBM) or different His tagged 
BAD mutations (4A, 128A, WT with no His tag, and WT) were created using retroviral 
infection as previously described [27].  The His-tagged BAD mutations were introduced 
into FL5.12 parental cells and cells already overexpressing BCL-xL.  The FBM construct 
was kindly made by Dr. Kwong-woon Kim (Vanderbilt University).  Briefly, 105 cells 
were combined with 500 µl purified virus and 1 µl polybrene.  Complete IMDM (c-
IMDM) media was added to this mixture to bring the total volume to 1 ml.  The cell 
mixture was gently pipetted and spun at 11,000 rpm for 60 minutes at room temperature, 
then pipetted to resuspend the cell pellet, and added into 4 ml complete IMDM with 4 µl 
polybrene, and incubated in an incubator kept at 37°C with 5% CO2.  This process was 
repeated three times, grown overnight, and then selected with 2 µg/ml puromyocin.  
HisBAD selected cells were pooled for further use.  A high expresser of FL5.12 FBM 
cells (M58) was further isolated by clonal selection. 
 
Kinase Assays 
To perform hot kinase assays, varying amount of substrate (0.2-1µg) was 
incubated in kinase buffer (containing an end concentration of 50mM Tris pH 7.4 and 10 
mM magnesium chloride), cold ATP (final concentration 0.2µM), and either purified 
kinase (p38 or CDC2) or total cellular lysate, at room temperature for 10 minutes.  Five 
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µCi 32P-γ-ATP (Perkins Elmer, Blu 502 H250uc) was added to the mixture and incubated 
at 30°C for 30 minutes.  If necessary, GST or His pull down was then performed, beads 
were washed three times in either isotonic buffer (containing 0.25% NP40, 10mMHepes 
pH7.5, 5mM MgCl2, 132.5 mM KCl) or nickel wash buffer (containing 20-40mM 
imidizole, 300mM NaCl, 50mM sodium phosphate pH7.8), 4x Laemmli sample buffer 
added, loaded on a 12.5% sodium dodecyl-sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE), transferred onto a Polyvinylidene fluoride (PVDF) membrane (MidSci 
#10-485-289) and visualized by autoradiography.  To perform cold kinase assays, the 
same steps were followed, omitting the addition of radiolabeled 32P ATP, and followed 
with western blotting with particular phospho-specific antibodies.   
 
Pull Down Experiments 
Cellular lysate was made by collecting cells, washing 3 times in PBS, adding 
isotonic buffer to the cell pellet, nutating the eppendorf at 4° for 20 minutes, performing a 
high speed (13k rpm) spin and collecting the supernate.  For all pull down experiments 
(GSH, microcystin, Flag, nickel), this total lysate was precleared with 10% sepharose 
beads (Sigma #2B300-100ml) incubated with agitation for 2 hours at 4°, spun at 
13,000rpm in a tabletop centrifuge, and supernate collected.  This precleared total lysate 
was then used for subsequent pull down experiments. 
GST-BAD pull downs were preformed on total lysate from FL5.12 cells over-
expressing GSTBAD or GST alone.  Ten percent the total lysate volume of GSH beads 
slurry (50/50 in isotonic buffer) was added to the pre-cleared cellular lysate and 
incubated with agitation for 2 hours at 4°.  After a high speed spin to pellet the GSH 
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beads, the beads were washed with isotonic buffer three times, and eluted in 100mM 
glutathione, 100mM Tris pH 7.5, 150mM NaCl.  Thrombin was a generous gift from 
members in Dr. Paul Bock’s lab (Pathology Department, Vanderbilt University).  
Thrombin cleavage to remove the GST tag from BAD in the GSTBAD constructs was 
preformed in accordance with the method proposed in Current Protocols in Molecular 
Biology, Enzymatic and Chemical Cleavage of Fusion Proteins, Supplement 28, 16.4.8. 
For microcystin pull downs, microcystin conjugated to beads (Upstate #16-147) 
added to pre-cleared cellular lysate, incubated with agination at 4° for 2 hrs, spun at 
13,000rpm in a tabletop centrifuge, supernate aspirated, beads washed three times with 
isotonic buffer, and beads collected. Beads would then either be western blotted or pulled 
down again to determine the presence or absence of suspected binding partners. 
 Flag pull downs were performed on the high expressing FL5.12 FBM cell line 
(M58) or pMSCV vector alone (p11).  Ten percent the total lysate volume of Flag bead 
(Sigma #A2220) slurry (50/50 in isotonic buffer) was added to the pre-cleared cellular 
lysate and incubated with agitation for 2 hours at 4°.  After being spun at 13,000rpm in a 
tabletop centrifuge to pellet the flag beads, the beads were washed with isotonic buffer 
three times, and eluted in 0.1 mg/ml freshly made 3x flag peptide (Sigma #F4799).  
 A reconstituted nickel chelated bead (Pierce #89827) in isotonic buffer (resulting 
in 50/50 slurry) was used to pull down His-Bad constructs expressed in FL5.12 cells. 
Total lysate was incubated with agitation with 10% volume His beads at 4° for 15 
minutes, pulse spun at 13,000rpm, washed three times with a 20-40mM imidazole buffer 
(optimized for experimental conditions), and aspirated with a 30G1 needle (BD 
#305128).   
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 Immunoprecipitation (IP) of over-expressed or endogenous proteins was also used 
to extract a specific protein complex from total lysate.  Bad C-20 (goat, Santa Cruz, 
sc943) was added to precleared cellular lysate at a concentration of 3µg antibody/200µg 
total lysate protein (approximately 1ml volume) and incubated with agitation at 4° for 2 
hours.  Ten percent protein A and G sepharose in isotonic buffer was then added to the 
total lysate/antibody slurry and incubated with agitation for another hour at 4°.  Beads 
were then spun down, washed three times with isotonic buffer, sucked dry with a 30G1 
needle, and prepared to be run on an SDS-PAGE gel with the addition of 4 x Laemmli 
sample buffer with 2-mercaptoethanol added to the dry beads.  
 
Cross-linking Protocol 
Aqueous soluble cross linkers (DTSSP and BS3, Pierce) were employed to 
determine nearby proteins.  Powdered cross linker was added directly to pre-cleared total 
lysate to a final concentration of 5mM, incubated with agitation for 2 hours at 4°, and 
then quenched with the addition of Tris-Cl pH 7.5 to a final concentration of 50mM for 
15 minutes at room temperature.  After quenching, a standard immunoprecipitation was 
carried out. 
 
Immunoblot Analysis 
One-dimensional SDS PAGE gels were run as previously reported [4].  Silver 
staining was performed following a protocol received from Dr. David Friedman [28].  
Native gels were run following the same protocol as SDS PAGE gels, except all SDS was 
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removed from the reagents making the lower, upper, Laemmli loading buffer, and 
running buffers.   
 
Proteomics Analysis 
The Mass Spectrometry Proteomics Core was essential for carrying out and 
analyzing many technically advanced methods including the following:  coating of SDS-
PAGE glass plates with Bind-Silane for subsequent Sypho Ruby picking, cy2/3/5 
imaging, extraction of protein gel bands, trypsin and chymotrypsin protein digestion, 
MS/MS and LC/MS running and analysis of samples, amino acid sequence analysis, 
phosphor-peptide identification, and focusing GSTBAD eluate samples on isoelectric 
strips for the commencement of a 2D gel.  All of these procedures were followed 
according to their in-house protocols.   
  
Ultra-Violet B (UVB) Radiation Experiments  
UVB experiments were performed by resuspending FL5.12 cells in 200µl 
complete IMDM media, plating these cells in 5 cm plates, exposing the uncovered dished 
to 60 µJ UVB radiation using a UV Stratalinker 1800 machine (Moses lab, Vanderbilt 
University), adding 4.8 ml c-IMDM to the plate under sterile conditions, and growing 
DNA damaged cells at 37°C with 5% CO2  for set time points.  
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CHAPTER III 
 
RESULTS 
 
Techniques examining BAD localization and GSTBAD complex binding partners 
The dissociation of 14-3-3 from BAD under conditions of cell death regulates 
BAD’s proapoptotic activity.  The dissociation of the BAD-14-3-3 binding event under 
conditions of cell death was hypothesized to involve the interaction of an unknown 
binding partner.  In this section, we examined and identified novel binding proteins to 
BAD under conditions of cell death and cell life.  
To examine the localization of BAD under conditions of cell death when protein 
phosphatase 2A (PP2A) has been reported to be bound, a PP2A inhibitor vector (pARP) 
was used.  After transient transfection with plasmids expressing pARP, which is localized 
either to the mitochondria or cytosol, NIH 3T3 cells were washed with PBS and placed in 
DMEM media without serum.  The cells were then collected at defined times, lysed, run 
on a SDS-PAGE gel, and western blotted for BAD dephosphorylation.  While cell death 
was observed using trypan blue hemocytometer counting, during the serum withdraw 
time BAD dephosphorylation (112, 136, 155) was not detected via western blot.  Because 
a reliable model for cell death in 3T3 cells could not be established, we could not 
reasonably pursue our original question of BAD localization while PP2A was unbound.   
In order to identify candidate proteins binding to BAD, we used GST-BAD fusion 
protein pull downs.  Aqueous-soluble cross linkers (DTSSP and BS3) were individually 
added to the GSTBAD total lysates to a final concentration of 5mM, run on a SDS PAGE 
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gel, western blotted for known binding partners and/or silver stained.  While western blot 
analysis detected the absence of 14-3-3 under cell death conditions, as expected, silver 
stained results did not visually yield notable differences between conditions.  Thinking 
that perhaps novel binding proteins may exist but were just not visible by silver stain, a 
shotgun approach was employed to determine potential binding partners.  With the help 
of the Mass Spectrometry Proteomics Core, a one-dimension SDS-PAGE gel of 
GSTBAD eluate samples from + and –IL3 conditions were stained with colloidal blue 
(Figure 2A).  Bands that appeared in one condition or the other were excised and 
identified using MS/MS.  The results yielded an extremely large overlap between the two 
conditions with only one protein, Rab1A (an ER localization protein involved with 
trafficking to and from the lysozome), emerging unique to in the –IL3 sample.  However, 
because two other Rab family members were identified in both experimental conditions 
(Rab11B and Rab7), and the unlikely co-localization of Rab 1A and BAD, these results 
were not pursued. 
Thinking that perhaps employing a difference of isoelectric points may help yield 
novel binding partners, a two dimensional approach was also attempted (Figure 2B) to 
examine bound proteins that may change under cell life and death conditions.  Eluates 
from GSTBAD expressing cells under cell life (+IL3) and death (-IL3 5hrs) conditions 
were used.  Samples were focused on a 3-10 pI strip, resolved in the second dimension on 
a 12.5% SDS-PAGE gel, and then stained for total proteins with fluorescent dyes 
(cy2/cy3/cy5).  However, again, there were no novel differences between the two 
conditions.  Using the DIGE 2D method to examine binding partners to BAD did not 
produce any candidate proteins.   
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Figure 2: Detection of different binding partners to GSTBAD under cell life and death 
conditions. A) Colloidal blue stain of GSTBAD eluate under + and – IL3 conditions.  
Indicated areas were picked and/or digested and sent for peptide analysis. 1=GST; 
2=GSTBAD +IL3; 3=GSTBAD –IL3 4hrs.  B) No difference observed by 2D cy3/5 
experiment between cell life or death (-IL3 5hrs) conditions.  GSTBAD was pulled down 
from cells grown under the indicated conditions, and eluted.  The eluate was then run on 
a pI3-10 strip in the first dimension and on a 12.5% SDS-PAGE gel in the 2nd 
dimension, and imaged fluorescently. 
Cy2 overlay
B 
A
1 2 3
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As a large amount of non-specific binding was thought to occur on the GST tag of 
the fusion protein, and hence when eluting off the GSH beads these nonspecific proteins 
would contaminate the BAD complex results, we then tried to release BAD from its GST 
tag using a specific protease, thrombin.  Thrombin was added to pulled-down GSTBAD; 
however, thrombin cleavage was inefficient in cutting only the GST tag from GSTBAD, 
and resulted in a highly degraded BAD protein.   
Using a double pull down—starting with a GSTBAD pull down, eluting, then 
following up with a BAD IP on the GSTBAD complex, and acid eluting off the 
GSTBAD complex—was the first attempt to clean up the GSTBAD eluate.  While this 
approach was attempted at three different temperatures (4°, 25°, and 34°C), all were 
unsuccessful, as shown in Figure 3.  As there were problems in getting the GSTBAD 
protein complex to acid elute off, other strategies were ultimately devised to twice-purify 
the BAD complex. 
 
 
 
p38 and CDC2 identified as binding partners of BAD 
 FL5.12 cells expressing a double tagged BAD construct (3X Flag-BAD-Myc) were then 
employed.  While the flag pull down and elution were successful (Figure 4A),  
Figure 3: Unsuccessful GSTBAD acid elution.  
GSTBAD pulled down on GSH beads was 
subjected to 100mM glycine pH1.8 at the 
designated temperatures for 30’, vortexing every 
5’, and western blotted for BAD. 
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         +            -7  
Adseverin      BAX alpha 
Cdc2       Beclin-1  
Cullin associated NEDD8    Coronin-1B 
Cytochrome c1 oxidase    Filamin A 
Dynamin-2      GRIP1-associated coactivator 63 
FK506-binding protein 4    Inducible 6-phosphofructo-2-kinase 
Flightless      Profilin 1 
Importin      Protein FAM3C precursor 
Serine/threonine protein kinase    Psmd1 protein 
     PLK1      Ran-binding protein 2 
Serine/threonine protein kinase 38   Reticulon protein 3 
Serine/threonine protein kinase SNF-    Ribose-phosphate                
     1 like kinase 2     Pyrophosphokinase I   
Serine/threonine protein kinase VRK2  Transgelin-3 
Voltage-dependent anion-selective  
      channel proteins 1, 2, and 3 
 
 
Figure 4:  FBM samples 
successfully elute from Flag beads. 
A) FL5.12 FBM or vector alone 
cells were lysed, pulled down with 
flag beads, eluted, and western 
blotted for total BAD. B) Silver 
stain of FBM eluate under cell life 
(+IL3) and death (-IL3 7hrs)  
conditions.   
 
Table 1: Proteins identified via Mass Spectrometry analysis of FBM complex.  Cells 
were grown under + or -IL3 (7hrs) conditions, collected, lysed, precleared, flag-pulled 
down, 3xflag peptide eluted, and sent to Mass Spectrometry on 3 different occasions.  
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eluting off the subsequent myc pull down was consistently unsuccessful.  Given that the 
myc beads may introduce another host of non-specific binding partners, a flag pull down 
and elution sample (a representative silver stain may be seen in Figure 4B) was sent to 
the Vanderbilt Proteomics Core for Mass Spectrum analysis for identification of binding 
partners on three different occasions.  While there were not overt visual differences from 
the silver stain eluate beside the presence or absence of the ~35kD FBM protein, the 
proteomics analysis yielded a spectrum of differences; Table 1 shows a list of screened 
results.  Based on suggestions in the literature, two kinases, CDC2 and p38, were then 
targeted as candidate proteins and followed up.  CDC2 has been reported to 
phosphorylate BAD at serine S128 [13].  
To validate the interaction of CDC2 and p38 with BAD in cells, overexpressed 
BAD, GSTBAD, or HisBAD was immunoprecipitated, pulled down with GSH or nickel 
beads from total lysate (under survival and death conditions) and immunoblot for the 
candidate p38 and CDC2 proteins.  As the results suggested no binding between BAD 
and p38 under either condition, we then employed crosslinker (DTSSP) to the total lysate 
before IPing BAD for western blot analysis.  Even using the crosslinker, there was no 
evidence of p38 interacting with BAD.  Conversely, p38 was IPed from total lysate and 
underwent western blot analysis for BAD, again showing no support for BAD-p38 
binding under cell life or cell death conditions.  While p38 was present on the HisBAD 
nickel pull downs, the binding was concluded to be nonspecific as the negative control 
(nickel beads incubated with total lysate that contained no His-tagged proteins) also 
contained the p38 band.  While p38 was identified in a mass spectrometry screen for 
BAD binding partners, there is no western blot evidence that p38 binds to BAD. As many 
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kinase substrates can be transient, it is reasonable to conclude from these data that the 
p38-BAD interaction is very transient. 
 
p38 phosphorylates a novel site on BAD 
As key phosphorylation events on BAD dictate the protein’s function, we then 
examined if any of the novel binding partners identified in Table 1 may phosphorylate 
BAD.  Starting in vitro, we then pursued the possibility of p38 being a novel kinase of 
BAD.  A hot kinase assay was performed using purified GSTBAD and p38 kinase.  The 
results (Figure 5A) suggested that while there was a modest phosphorylation of wild-type 
BAD and a GSTBAD 128A mutant by p38, when 112, 136, and 155 serine sites were all 
mutated to alanine (3A), p38 greatly phosphorylated BAD.  This membrane was then 
western blotted for the phosphorylation of S128 BAD and total BAD.  Figure 5A 
suggested that while CDC2 does phosphorylate BAD at S128 as reported [13], p38 
phosphorylated BAD on a site that is not 128.  While this hot kinase assay result was 
repeated numerous times, and at all times there has been a strong signal of p38 
phosphorylating GSTBAD 3A, the WT and 128A proteins were not always 
phosphorylated by p38.  A HisBAD 4A (112, 128, 136, 155) construct was then made 
and also underwent a hot kinase assay with p38; due to subcloning difficulties the 
HisBAD 3A was unavailable for this experiment, so the GSTBAD 3A was used.  As seen 
in Figure 5B, the 4A mutation was not phosphorylated by p38.  However, as neither was 
the wild type HisBAD in this experiment, the result is difficult to interpret.  Combined, 
these data suggested that p38 may phosphorylate a novel site on BAD, one that is not 
serine 112, 128, 136, or 155.   
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Figure 5: p38 phosphorylates a novel site on BAD.   A) A hot kinase assay using  
purified p38 or CDC2 with GSTBAD mutants.  B) Bacterially expressed and purified 
HisBAD WT and mutants (4A, 128A) and GSTBAD3A (all on beads) underwent a  
hot kinase assay with p38, was autoradiographed, and then probed for total BAD.  
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Figure 6: BAD is phosphorylated in vitro under conditions of cell death A)  100µg total 
lysate of FL5.12 parental cells were added to HisBAD in a hot kinase assay and 
autoradiographed  B) FL5.12 parental cells were pretreated with a specific inhibitor to 
p38 (10 µM) or CDC2 (20 µM), washed three times with PBS, put in + or –IL3 media, 
grown for 7hrs, then lysed, added to commercial HisBAD in a hot kinase assay, and 
autoradiographed C) both p38 (10 µM) and CDC2 (20 µM) inhibitors were 
simultaneously added to FL5.12 cells under conditions of growth or death, lysed, applied 
to HisBAD in a hot kinase assay, and audioradiographed. 
 
 
 
With our encouraging in vitro results, we then examined the phosphorylation 
status of BAD in growing cells.  FL5.12 parental cells growing under healthy (+IL3) or 
cell death conditions (-IL3 for 7hrs), were lysed, and added to a HisBAD substrate in a 
hot kinase assay.  Figure 6A suggested there were kinases still active under cell death 
conditions that are able to act upon BAD.  In panel B, FL5.12 parental cells were 
pretreated for 30 minutes with a specific inhibitor to either p38 (SB203580 at 10µM) or 
CDC2 (olomoucine at 20µM), washed three times with PBS, placed in either survival or 
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death media, and inhibitors to either p38 (10µM) or CDC2 (20µM) reintroduced.  
Growing cells were then collected after 7 hours, lysed, and added to commercial HisBAD 
in a hot kinase assay.  There was no difference in the phosphorylation of BAD with or 
without p38 inhibitor, in growing or cell death conditions.  BAD was phosphorylated by 
cellular kinases that were not p38 or CDC2 even under cell death conditions.  When both 
p38 and CDC2 inhibitors were added to growing or dying cells, Figure 6C again 
suggested that BAD was still phosphorylated when both p38 and CDC2 were presumably 
inactive.  Given the many kinases known to phosphorylate BAD, these results are not 
surprising. 
We attempted to preserve BAD’s novel phosphorylation site(s) by using 
trichloroacetic acid (TCA) precipitation from cellular lysate, performed as previously 
reported [29].  However, despite increasing the amount of resolubization time and 
percentage of TCA, I was unable to resolubilize BAD into in the urea resolubilization 
buffer following TCA protein precipitation.  Because of technical problems, the TCA 
approach was aborted. 
In order to determine if there was a difference in cell survival due to BAD 
mutation, HisBAD constructs (4A, 3A, 128A, and WT) were introduced in FL5.12 Bclx 
cells by retroviral infection.  Cells were then washed 3 times with PBS, plated in –IL3 
media, and live and dead cells counted using trypan blue dye and a hemocytometer.  
Figure 7 indicates that the different HisBAD mutations did not have a different effect on 
cell survival. However, the expression levels of the constructs were not equivalent, so this 
experiment needs to be repeated normalizing construct expression levels before a 
conclusion can be drawn.     
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In order to determine where p38 phosphorylates wild type BAD, a cold kinase 
assay of commercial HisBAD and p38 was conducted, run on a SDS-PAGE gel, colloidal 
blue stained (Figure 8A), bands excised, and sent to the Mass Spectrometry Proteomics 
Core for phospho-peptide analysis.  A small scale hot kinase assay was done in parallel to 
confirm that the p38/HisBAD sample sent was phosphorylated (Figure 8B).  There was 
good coverage of the HisBAD protein sent to the proteomics core with the trypsin and 
chymotrypsin digestions.  Phosphopeptide analysis implicated serine six on BAD (a site 
that has not been previously reported to be modified) as a possible p38 phosphorylation.  
While this serine 6 site does not contain the conserved MAPK consensus motif P-X(1-2)-
T/S-P [30, 31], possessing instead 3KQPSLAP9, it may prove to be a novel 
phosphorylation site. 
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Figure 7: Survival curve of FL5.12 Bclx HisBAD mutant cells.  Cells were washed 3x 
with PBS, put in –IL3 media, and counted at indicated times for live and dead cells using 
trypan blue on a hemocytometer.  Percent alive calculated by dividing the number of 
alive cells by the total number of cells (alive and dead) counted. 
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Figure 8: Submission for Mass Spectrometry Phosphopeptide analysis.  A) Colloidal blue 
stain on cold kinase assay using either purified p38 or PKA on substrate HisBAD.  
HisBAD bands were then excised, digested with trypsin and chymotrypsin, and analyzed 
for changes in mass.  B) Hot kinase assay of p38 and PKA kinases on HisBAD. 
 
 
p38 may be activated under UVB radiation 
As p38 emerged as an in vitro kinase of BAD, I then pursued establishing a model 
in which p38 activation could be experimentally controlled; I first examined conditions in 
which p38 is active.  Since the literature suggested that p38 is active in cells under 
conditions of arrest [32], this model was first examined.  However, p38 appeared active 
in both cycling and arrested 3T3 cells in my hands (Figure 9A).  This model was not 
pursued. 
As p38 emerged as a potentially interesting kinase for BAD, we attempted to 
determine when p38 is active in FL5.12 cells.  IL3 was withdrawn from FL5.12 cells for 
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up to 3 hours and then, in one sample, IL3 was added back and cells grown for 30 
minutes (Figure 9B).  As a change in active p38 was not observable under these 
conditions, other stressors were tried to activate p38.  FL5.12 cells were exposed to heat 
shock or varying microjoules (µJ) of UVB radiation, collected over a time course, lysed, 
and western blotted for active and total p38.  While the heat shock had no effect on p38 
activation, there was some weak evidence that 26 hours after 60 µJ UVB radiation, cells 
 
 
 
Figure 9: Examining when p38 is active in 3T3 and FL5.12 cells.  A)  3T3 cells arrested 
or cycling both have active p38.  Contrary to reports in the literature, cycling cells seems 
to have more active p38.  B) IL3 was withdrawn from FL5.12 cells for the indicated 
times, and then reconstituted.  C) FL5.12 cells were exposed to 60 uJ UVB radiation, 
grown in c-IMDM for indicated times (in hours) before collection, lysed, and subjected to 
western blotting. 
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had elevated levels of active p38 (Figure 9C).  However, as this single time point 
showing p38 activation was immediately preceded by two inactive time points (22 and 
24hrs) and, in a separate experiment, a 28 hour time period also had low levels of p38 
activation, one must interpret these data cautiously.  The experiment needs to be repeated 
to include hourly time points between 22 and 28 hours post UVB radiation in order to 
draw conclusions about the timing of p38 activation after exposure to UVB radiation. 
 
BAD modification studies 
As BAD is known to have several sites of phosphorylation events that are central 
to its regulation and function, we then pursued the question of there were other, 
undiscovered modifications on BAD under conditions of cell death.  To examine if BAD 
underwent novel post translational modifications under conditions of cell death, we 
employed a 2 dimensional gel and looked for a spot shift representing the gain or loss of 
a phosphate group.  Running GSTBAD eluate on a 3-10 pI strip and examining the 
results yielded no conclusive evidence for a novel BAD phosphorylation site under 
healthy or cell death conditions (Figure 10).  As there were no points of reference (ex: 
actin) to line up the blots, the results were difficult to compare to each other.  Advice 
from Dr. David Friedman suggested that overloading and/or using too broad an 
isoelectric strip may have contributed to the suboptimal focusing observed here.   
 
BAD serine 128 is activated under conditions of cell death 
As the phosphorylation of BAD at serine 128 has been implemented as a key site 
that dissociates BAD from 14-3-3 when undergoing the G2/M phase in growing lymphoid 
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cells, and in inducing cell death when deprived of growth factors and being in the G2/M 
phase [16], we then examined if this site may have a role in cell death independent of cell 
cycle.  Total lysate was made from FL5.12 cells over expressing BAD and BCL-xL 
during a time course of IL3 withdraw and western blotted with an antibody for the 
phosphorylation of S128 BAD (Figure 11A).  The phosphorylation of BAD 128 is low 
under cell growth conditions and under minus IL3 conditions for up to half an hour.  
However, when cells have been in media without IL3 for 3 hours or more, there is an 
increase of phosphorylation at BAD S128.  The phosphorylation of S128 was identified 
during induction of cell death.  In a different cell line over expressing 3xFlag-BAD-Myc, 
a similar effect of BAD 128 phosphorylation under –IL3 conditions for 7 hours was also 
observed (Figure 11B).  While this experiment was highly reproducible with one working 
solution of the p128 antibody (from Bonnie), subsequent dilutions of both commercial 
and homemade (Bonnie) antibodies have not suggested any phosphorylation of BAD at 
128 under conditions of IL3 withdraw.  It is conceivable that the polyclonal commercial 
antibody batches were not as sensitive and had a lower concentration of antigens specific 
to the p128 site as did the original p128 (Bonnie) antibody.  Furthermore, it is possible 
that the homemade (Bonnie) antibody, stored at 4°, degraded over time and lost its ability 
to bind the phosphorylated 128 BAD epitope.      
 
 
 
 
Figure 10: No clear evidence for 
GSTBAD eluate post 
translational modification using 
2D gels.  GSTBAD eluate from 
cell life (+IL3) and death (-IL3 
5hrs) conditions run on a 2D gel 
(3-10 pI strip). Examining the 
dot shifts yielded no conclusive 
evidence for a novel BAD 
phosphorylation site under 
healthy or cell death conditions. 
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Figure 11: Phosphorylation at BAD S128 is observed under conditions of cell death.  A) 
FL5.12 cells overexpressing BAD and Bcl-x (WTN1) were subjected to –IL3 conditions 
for indicated times; total lysate was then run on a SDS-PAGE gel and immunoblotted. B) 
FL5.12 cells expressing FBM construct was subjected to cell death conditions for 
indicated times, lysed, and western blotted. 
    
 
ATM/ATR does not affect BAD or 14-3-3 Phosphorylation 
ATM/ATR kinases are responsive to DNA damage and are known to have a TQ 
and SQ consensus sequence [33]; as murine BAD has both TQ and SQ sites near the end 
of its sequence, it was deemed possible that ATM/ATR may phosphorylate BAD to 
induce a modification.  ATM/ATR kinases were examined as potential agents acting 
upon BAD using hot kinase assays (using purified ATM/ATR, their kinase dead or 
inhibited equivalent, and HisBAD).  There was no evidence of a 32P band corresponding 
at the size of HisBAD (~36kD) or His14-3-3 (~42kD) with either ATR or with ATR’s 
inhibitor caffeine added; a similar lack of difference was also observed with the ATM hot 
kinase assays.  I found no evidence for ATM/ATR phosphorylation of BAD or 14-3-3. 
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Modification of 14-3-3 studies    
14-3-3 proteins are usually found as functional dimers in cells; however, there 
was a report of 14-3-3 monomers existing and retaining the ability to bind downstream 
targets [18].  In order to determine if 14-3-3 may monomerize during conditions of cell 
life or death, cells with or without IL3 survival factor (and with or without R18, a 
competitive peptide to 14-3-3) were lysed, 14-3-3 was IPed from total lysate, and then 
run on SDS or native gels.  One would expect the dimer to be approximately twice the 
size of the monomer on native gels.  I found no shift in the molecular weight of 14-3-3 
from dimer to monomer under conditions of cell death (Figure 12).  There was no 
evidence that monomerization was a mechanism of 14-3-3 dissociation from BAD under 
IL3 withdrawal.  
  
 
 
 
 
Figure 12: 14-3-3 does not monomerize 
under conditions of cell death.  FL5.12 
parental cells were grown under +IL3 (+) or 
–IL3 (-) conditions for 7 hours, lysed, run on 
SDS or native gels, and western blotted for 
14-3-3.  Kaleidoscope markers (indicated by 
the tick marks) were run on both gels in 
order to estimate the native protein size. 
 
  
 
While 14-3-3 is a key regulator that acts as a phosphoserine/phosphothreonine-
binding protein [18, 19] [17], it is also subject to modifications that alter 14-3-3’s ability 
31 
to bind to targets.  We then examined if 14-3-3 may undergo a 
modification/phosphorylation under conditions of cell death that encourages its 
dissociation from BAD.   
A phosphorylation change of 14-3-3 (which has also been reported [25, 34]) will 
result in a different isoelectric point.  We used 2D gel electrophoresis to examine both 
14-3-3 that bound GSTBAD and unbound 14-3-3 under cell death conditions (Figure 13).  
Figure 13A shows a 14-3-3 western blot of a 2D gel.  Since focusing was suboptimal, this 
protocol was repeated using a narrower isoelectric strip (pI 4-7) more attuned to the pI of 
14-3-3 (pI 4.5); the results are shown in Figure 13B.  Because there was not an obvious 
new spot to suggest a new phosphorylation event, I decided not to pursue this line of 
experimentation.  This experiment may have been suboptimal; technical improvements 
on performing a 2D gel include loading less protein and having a common reference 
point in all three blots in order to accurately line up the developed blots.  
To look more globally for 14-3-3 modifications under conditions of cell life and 
death, a 2D experiment was conducted with a narrower pI strip (3-5.5) to allow for even 
better focusing.  After total lysate from growing and cell death conditions was focused on 
the pI 3-5 strips, samples were run in the second dimension on a SDS PAGE gel and 
compared using cy3/5 fluorescent staining.  The overlay (Figure 14) identified a single 
spot which was different between life and death conditions.  This spot was later identified 
as translation initiation factor 5A.  No 14-3-3 modification spot was detected under 
conditions of cell life and cell death using DIGE 2D.  
One study has suggested that 14-3-3 phosphorylation altered its structure  
(becoming a monomer) [18], while another report has implicated JNK in phosphorylating  
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Figure 13: 14-3-3 modifications can not be clearly detected on a 2D gel.  A) 
GSTBAD eluate run on 2D gel, pI strip 3-10 in the first dimension, 12.5% SDS Page 
gel in the second dimension. Western blotted for 14-3-3.  B) Total lysate was 
analyzed on a 2D gel (pI 4-7) under indicated cell death conditions and western 
blotted for 14-3-3.   
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Figure 14: No new 14-3-3 modification was detected under cell death induction.  2D 
analysis of total lysate from cell life and death conditions (-IL3, 7hrs) displays a 
phosphorylation shift in translation initiation factor 5A 
 
 
14-3-3 to release it from binding Bcr-Abl [25].  We explored the possibility that JNK 
may phosphorylate 14-3-3 to release it from BAD.  We hypothesized that if JNK 
phosphorylated 14-3-3 to aid in its dissociation from BAD, then preventing this 
phosphorylation event would lead 14-3-3 to remain associated with BAD even in –IL3 
conditions and render BAD more phosphorylated at key sites protected by the bound 14-
3-3.  Using a JNK specific chemical inhibitor (SP600125, 10µM), total lysates were 
collected, BAD immunoprecipitated, and western blotted for BAD-14-3-3 binding and 
BAD phosphorylation status.  Figure 15 demonstrates that BAD was successfully 
Cy2 0pH 3 pH 5.5
~200 kDa 
~10 kDa 
actin 
isoforms   
ca. 42 kDa, 
5.3 pI 
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immunoprecipiated, as indicated by the presence of BAD on the (protein A/G) beads.  
However, the positive control (beads under +IL3 conditions) did not demonstrate what 
was expected (the presence of BAD).  Therefore, this experiment is difficult to interpret.  
During the time these experiments were conducted, a report was published confirming 
that JNK phosphorylates 14-3-3 to allow the release of BAD [21]. 
 
 
 
 
          
 
   
 
 
From the candidate proteins identified from the BAD pull down, p38 and CDC2 
emerged as potential candidate kinases that may interact with the BAD complex, 
including 14-3-3.  For this reason, we performed a hot kinase assay to see if 14-3-3 was 
modified by either p38 or CDC2 kinases as well as using total lysate from different death 
conditions (+IL3, -IL3 3hrs, -IL3 7 hrs) (Figure 16).  Unfortunately, the GST tag was 
discovered to be phosphorylated by CDC2 (see Figure 5), and there was no evidence that 
Figure 15: No conclusive evidence JNK has an effect on 14-3-3 binding BAD.  
FL5.12 cells overexpressing Bclx and BAD (WTN1) were treated with JNK inhibitor 
(SP600125, 10µM) under the indicated conditions, IPed with BAD goat C-10, and 
subject to western blotting.
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p38 phosphorylated 14-3-3.  It appeared that under +IL3 or –IL3 conditions there are 
cellular kinases which can phosphorylate 14-3-3.     
 
Figure 16:  No evidence p38 or CDC2 phosphorylates 14-3-3.  FL5.12 parental cells total 
lysate under 0, -3, or -7 hours of IL3 deprivation was one source of kinases.  
Additionally, purified p38 and CDC2 were also used as kinases against the substrate GST 
14-3-3 in a hot kinase assay. 
 
 
Results Summary 
 Several novel binding partners to BAD were identified that existed in either a 
condition of cell life or cell death; this list included: p38, CDC2, Beclin-1, BAX, 
cytochrome c1 oxidase, voltage-dependent anion-selective channel proteins 1, 2, and 3, 
FK506-binding partner 4, and kinases PLK1, SNF-1 like kinase 2, and VRK2.  While p38 
and CDC2 were followed up, other binding partners identified here may warrant deeper 
investigations. 
 Hot kinase assays suggested that p38 phosphorylates a novel site on BAD, 
perhaps serine 6.  Since p38 activation was not observed during times BAD 128 has 
Gst 14-3-3
autoradiograph 
36 
shown to be active, it is unlikely that p38 phosphorylates BAD S128.  Using in vitro 
techniques, BAD was shown to be phosphorylated under both +IL3 and –IL3 conditions 
from cellular kinases.  The phosphorylation state of BAD S128 was observed after 3-7 
hours of –IL3.  No evidence was observed for ATM/ATR phosphorylation of BAD or 14-
3-3. 
 Under +IL3 and –IL3 conditions, no new phosphorylation sites or monomeric 
changes on 14-3-3 were observed.  Additionally, p38 was concluded not to phosphorylate 
14-3-3, although under both +IL3 and –IL3 conditions, there was evidence that 14-3-3 
was phosphorylated by cellular kinases. 
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CHAPTER IV 
 
DISCUSSION 
 
In this study, we demonstrate the possibility of a novel phosphorylation site on 
BAD.  In vitro data suggest BAD S6 may be phosphorylated by p38.  There are a number 
of follow up experiments that could be conducted to support or refute this finding.  In 
order to confirm p38 phosphorylates BAD S6, a cold in vitro kinase assay using a clean 
recombinant WT or S6A could be conducted, then sent to Mass Spectrometry for 
phosphopeptide analysis.  Additionally, to examine if the phosphorylation state at other 
sites on BAD affects p38’s ability to phosphorylate S6, other BAD mutants (112A, 128A, 
136A, 155A, and all combinations) could also be used in vitro kinase assays.  Although 
the biological significance of this novel serine 6 site is currently unknown, it may act as 
another regulatory phosphorylation event on BAD, perhaps linking the p38 MAPK 
signaling pathway with the apoptotic machinery. 
To verify that p38 does phosphorylate BAD in FL5.12 cells, a hot in vivo cellular 
experiment could be conducted with and without a dominant negative p38.  Different 
HisBAD mutants (3A, 4A, WT, S112A, S128A, S6A) could be pulled out of the total 
lysate, and immunoblotted for specific phosphorylation events.  Additionally, culturing 
cells expressing a BAD WT, S6A, 3A, and 4A mutation under conditions that activate 
p38 may also aid in identifying a p38 phosphorylation site.     
A previous study has suggested that in tumor necrosis factor α (TNF)-induced 
apoptosis in endothelial cells, p38 regulates phosphorylation of BAD S112, in addition to 
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coimmunoprecipitating with PP2A [22], a known phosphatase of the S112 site of BAD 
[4].  While this study did not examine other known phosphorylation sites on BAD, it is 
possible that TNF induced apoptosis stimulates other known and novel phosphorylation 
sites on BAD, such as S6.  
There is much known about the phosphorylation of BAD and how that regulates 
binding partners, cell cycle under growth factor deprivation/starvation conditions, and 
apoptosis [8, 13, 14, 16]; however, the significance for the phosphorylation of S128 BAD 
on survival in the FL5.12 cell model deserves elucidation. Since the original experiments 
in which phosphorylation of 128 was observed did not use arrested or synchronized cells, 
it is unlikely that this phosphorylation event was cell cycle dependent (as has been 
suggested by another report [16]).  Immunoprecipitating BAD when it is known to be 
phosphorylated at S128 and looking for different binding partners may warrant follow up.   
One may want to reevaluate the binding partner data to pursuing other potentially 
interesting proteins from this list.  Cytochrome c1 oxidase, the voltage-dependent anion-
selective channel proteins, BAX, and beclin-1  are all proteins yielded from a Mass 
Spectrometry binding analysis (Table 1) that are known to be involved in the apoptosis or 
autophagosome pathways, and warrant follow up study.  Furthermore, the Rab1A protein 
(identified in analyzing an one-dimension SDS-PAGE gel of GSTBAD eluate samples 
from cell life and death conditions, Figure 2A) may also be reexamined in light of the 
autophagosome pathway.  Studies looking at the localization patterns of candidate Rab 
proteins and BAD under conditions of cell death or autophagy may uncover a connection 
between the Rab family to the cell death machinery pathway, as other members of the 
Bcl-2 family have been indirectly linked with autophagy [35].  
39 
The literature has provided several examples of 14-3-3 modification and cleavage 
to facilitate dissociation from target proteins [18, 20, 25, 34]; there has even been a 
particular report of caspace-3 cleavage of 14-3-3 at D238 which facilitates the 
dissociation of BAD in human 293T cells [34].  The data collected here using IL-3 
deprivation as the death stimulus has not produced any observable modification of 14-3-
3.  Performing a double pull down—first on 14-3-3 and then BAD—may enrich for other 
interacting proteins in the 14-3-3 BAD complex.   
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